SignalXSignalX

ACTUATE THERAPEUTICS, INC. (ACTU) Q3 2025 10-Q Quarterly Report

Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
ACTUATE THERAPEUTICS, INC. Overview

ACTUATE THERAPEUTICS, INC. (ACTU) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

ACTUATE THERAPEUTICS, INC. Q3 2025 10-Q Analysis

Risk Factors

  • • No new or materially updated risk factors disclosed compared to most recent 10-K
  • • Regulatory risk: ongoing compliance with FDA and global regulatory bodies remains critical for product approvals
+2 more insights

ACTUATE THERAPEUTICS, INC. Q3 2025 Quarterly Financials
XBRL

Net Income

-$5M

▲ +9.4% YoY▲ +9.1% QoQ

ROE

-49.4%

Total Assets

$18M

EPS (Diluted)

$-0.25

▼ -104.9% YoY▲ +19.4% QoQ

Operating Cash Flow

-$7M

▲ +27.0% YoY▼ -60.0% QoQ

Source: XBRL data from ACTUATE THERAPEUTICS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on ACTUATE THERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.